Abstract：
The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, accompanied by extensive positive media attention and private equity investment. Government regulatory bodies in Australia, Israel, Canada and the United States now permit use of psychedelics for medical purposes. In the United States, citizen action and corporate financing have led to petitions and ballot initiatives to legalize psilocybin and other psychedelics for medical and recreational use. Given this momentum, policymakers must grapple with important questions that define whether and how psychedelics are made available to the public, as well as how companies produce and promote them. The current push to broaden the production, sale, and use of psychedelics bears many parallels to the movement to legalize cannabis in the United States and other nations-most notably, the use of poorly-evidenced therapeutic claims to create a de facto recreational market via the health care system. Experience with cannabis highlights the value of debating the question of legalization for nonmedical use as such rather than misrepresenting it as a medical issue. The lessons of cannabis policy also suggest a need to challenge hyping of psychedelic research findings; to promote rigorous clinical research on dosing and potency; to minimize the influence of for-profit industry in shaping policies to their economic advantage; and to coordinate federal, state, and local governments to regulate the manufacture, sale and distribution of psychedelic drugs (regardless of whether they are legalized for medical and/or recreational use).
摘要：
世纪之交带来了对迷幻药的兴趣，作为成瘾和其他精神疾病的治疗方法，伴随着媒体的广泛积极关注和私募股权投资。澳大利亚政府监管机构，以色列,加拿大和美国现在允许将迷幻药用于医疗目的。在美国,公民行动和公司融资导致了请愿和投票倡议，以使psilocybin和其他迷幻药合法化，用于医疗和娱乐用途。鉴于这种势头,政策制定者必须努力解决重要的问题，这些问题定义了迷幻药是否以及如何向公众提供，以及公司如何生产和推广它们。当前推动扩大生产，sale,迷幻药的使用与美国和其他国家的大麻合法化运动有许多相似之处——最值得注意的是，使用证据不足的治疗声称通过医疗保健系统创建事实上的娱乐市场。大麻的经验凸显了辩论非医疗用途合法化问题的价值，而不是将其误认为是医疗问题。大麻政策的教训还表明，有必要挑战对迷幻研究结果的炒作；促进关于剂量和效力的严格临床研究；尽量减少营利性行业在制定政策以实现其经济优势方面的影响；并协调联邦，state,和地方政府来规范生产，销售和分销迷幻药（无论它们是否合法用于医疗和/或娱乐）。
